Idexx Laboratories Extends Rally Following Upbeat Q3 Earnings, Outlook

IDEXX Laboratories (IDXX) reported better-than-expected third-quarter 2025 financial results, with adjusted EPS of $3.22 and sales of $1.105 billion, both surpassing consensus estimates, driven by strong growth across its Companion Animal Group and Poultry and Dairy segments. The company subsequently raised its full-year 2025 earnings and sales guidance, projecting higher revenue and organic growth rates. This positive performance and outlook led to a significant 13.99% increase in IDXX stock, with analysts noting the results provide reassurance regarding the company's ability to meet expectations despite ongoing end-market challenges.

Analysis

IDEXX Laboratories (IDXX) reported robust third-quarter 2025 financial results, exceeding consensus with adjusted EPS of $3.22 (up 15% YoY) and sales of $1.105 billion. Performance was driven by strong Companion Animal Group (CAG) sales, up 13% reported and 12% organic, and Poultry and Dairy (LPD) revenue growth of 17.1% reported. Gross margin expanded 70 basis points to 61.8%, and operating margin rose 100 basis points to 32.1%, supported by productivity and net price realization.

The company subsequently raised its fiscal 2025 earnings guidance to $12.81-$13.01 per share and sales guidance to $4.27 billion-$4.30 billion, both surpassing prior ranges and consensus estimates. This updated outlook projects higher reported revenue growth of 9.6%-10.3% and organic growth of 8.8%-9.5%. The market responded positively, with IDXX stock trading up 13.99% at $717.55, reflecting strong investor confidence.

William Blair analyst Ryan Daniels highlighted that despite recognized end-market weakness, IDEXX's results reassure investors of its capacity to meet expectations. Strong CAG Diagnostics recurring revenue growth, particularly internationally (18% reported, 14% organic), and effective inflationary management underscore operational resilience. The analyst maintains an Outperform rating, anticipating future EPS growth to drive further share appreciation.

Key Decisions for Investors

• Investors should consider the significant Q3 earnings and sales beat, alongside the raised 2025 guidance, as a strong indicator of IDEXX's operational strength and positive outlook
• Monitor the sustainability of international CAG Diagnostics recurring revenue growth and the company's continued ability to offset end-market pressures through pricing and productivity initiatives
• Evaluate the stock's current valuation, given its near-record highs, against the updated guidance to determine appropriate position sizing